3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Renal Cell
7
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Carcinoma, Hepatocellular
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uveal Melanoma
1
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Kidney Neoplasms
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Cystadenocarcinoma, Serous
1
Colonic Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Interventions
Fluorouracil
25
Oxaliplatin
24
Irinotecan
24
Leucovorin
23
Bevacizumab
23
Capecitabine
18
Cetuximab
15
Radiotherapy
6
Gene Expression Profiling
5
regorafenib
4
Immunohistochemistry
4
Gemcitabine
4
Folfox protocol
4
Colonoscopy
4
Cisplatin
4
Celecoxib
4
Amplified Fragment Length Polymorphism Analysis
4
Reverse Transcriptase Polymerase Chain Reaction
3
Receptor Protein-Tyrosine Kinases
3
Polymerase Chain Reaction
3
Nivolumab
3
Mitomycin
3
Doxorubicin
3
Cyclophosphamide
3
Cholecalciferol
3
Biopsy
3
Aspirin
3
sargramostim
2
pembrolizumab
2
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Colonic Neoplasms
×
Axitinib
×
Clear all
NCT04873895
2024-04-26
TACE-Ax-HCQ
Abramson Cancer Center at Penn Medicine
Phase 1
Terminated
5 enrolled